NASDAQ:KIN - Kindred Biosciences Stock Price, Price Target & More

$8.85 -0.20 (-2.21 %)
(As of 04/26/2018 09:30 AM ET)
Previous Close$9.05
Today's Range$8.85 - $9.35
52-Week Range$6.50 - $9.80
Volume106,600 shs
Average Volume84,572 shs
Market Capitalization$255.11 million
P/E Ratio-7.20
Dividend YieldN/A
Beta0.08

About Kindred Biosciences (NASDAQ:KIN)

Kindred Biosciences logoKindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company's lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company's other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.

Receive KIN News and Ratings via Email

Sign-up to receive the latest news and ratings for KIN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KIN
CUSIPN/A
Phone650-701-7901

Debt

Debt-to-Equity RatioN/A
Current Ratio13.59%
Quick Ratio13.59%

Price-To-Earnings

Trailing P/E Ratio-7.20
Forward P/E Ratio-5.90
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.00 per share
Price / Book2.95

Profitability

EPS (Most Recent Fiscal Year)($1.23)
Net Income$-30,870,000.00
Net MarginsN/A
Return on Equity-38.00%
Return on Assets-36.29%

Miscellaneous

Employees63
Outstanding Shares28,190,000

How to Become a New Pot Stock Millionaire

Kindred Biosciences (NASDAQ:KIN) Frequently Asked Questions

What is Kindred Biosciences' stock symbol?

Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."

How were Kindred Biosciences' earnings last quarter?

Kindred Biosciences (NASDAQ:KIN) announced its quarterly earnings data on Thursday, March, 1st. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing the Zacks' consensus estimate of ($0.33) by $0.02. View Kindred Biosciences' Earnings History.

When is Kindred Biosciences' next earnings date?

Kindred Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Kindred Biosciences.

What price target have analysts set for KIN?

6 analysts have issued twelve-month price objectives for Kindred Biosciences' stock. Their predictions range from $8.00 to $11.00. On average, they expect Kindred Biosciences' share price to reach $10.10 in the next year. View Analyst Ratings for Kindred Biosciences.

Who are some of Kindred Biosciences' key competitors?

Who are Kindred Biosciences' key executives?

Kindred Biosciences' management team includes the folowing people:
  • Wendy Wee, Chief Financial Officer (Age 64)
  • Denise M. Bevers, Chief Operating Officer, Secretary (Age 47)
  • Hangjun Zhan, Chief Scientific Officer
  • Herbert D. Montgomery, Independent Director (Age 68)
  • Raymond Townsend, Independent Director (Age 70)
  • Ervin Veszpremi, Independent Director (Age 56)

Has Kindred Biosciences been receiving favorable news coverage?

Media headlines about KIN stock have been trending somewhat positive recently, according to Accern Sentiment. Accern scores the sentiment of press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Kindred Biosciences earned a media sentiment score of 0.15 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 45.34 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

How do I buy shares of Kindred Biosciences?

Shares of KIN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kindred Biosciences' stock price today?

One share of KIN stock can currently be purchased for approximately $8.85.

How big of a company is Kindred Biosciences?

Kindred Biosciences has a market capitalization of $255.11 million. The biopharmaceutical company earns $-30,870,000.00 in net income (profit) each year or ($1.23) on an earnings per share basis. Kindred Biosciences employs 63 workers across the globe.

How can I contact Kindred Biosciences?

Kindred Biosciences' mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The biopharmaceutical company can be reached via phone at 650-701-7901 or via email at [email protected]


MarketBeat Community Rating for Kindred Biosciences (KIN)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  168 (Vote Outperform)
Underperform Votes:  182 (Vote Underperform)
Total Votes:  350
MarketBeat's community ratings are surveys of what our community members think about Kindred Biosciences and other stocks. Vote "Outperform" if you believe KIN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KIN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Kindred Biosciences (NASDAQ:KIN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Kindred Biosciences in the last 12 months. Their average twelve-month price target is $10.10, suggesting that the stock has a possible upside of 14.12%. The high price target for KIN is $11.00 and the low price target for KIN is $8.00. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.673.00
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $10.10$10.10$9.90$9.00
Price Target Upside: 14.12% upside13.48% upside3.13% upside29.50% upside

Kindred Biosciences (NASDAQ:KIN) Consensus Price Target History

Price Target History for Kindred Biosciences (NASDAQ:KIN)

Kindred Biosciences (NASDAQ:KIN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/2/2018HC WainwrightSet Price TargetBuy$11.00HighView Rating Details
12/27/2017CL KingInitiated CoverageNeutral -> NeutralLowView Rating Details
12/22/2017BMO Capital MarketsReiterated RatingHoldHighView Rating Details
12/15/2017AegisReiterated RatingBuyLowView Rating Details
12/5/2017B. RileySet Price TargetBuy$11.00LowView Rating Details
5/31/2017FBR & CoReiterated RatingBuyLowView Rating Details
1/3/2017Feltl & Co.Reiterated RatingStrong-BuyN/AView Rating Details
11/1/2016Ladenburg ThalmannInitiated CoverageBuy$7.50N/AView Rating Details
(Data available from 4/26/2016 forward)

Earnings

Kindred Biosciences (NASDAQ:KIN) Earnings History and Estimates Chart

Earnings by Quarter for Kindred Biosciences (NASDAQ:KIN)

Kindred Biosciences (NASDAQ:KIN) Earnings Estimates

2018 EPS Consensus Estimate: ($1.37)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.33)($0.33)($0.33)
Q2 20181($0.35)($0.35)($0.35)
Q3 20181($0.34)($0.34)($0.34)
Q4 20181($0.35)($0.35)($0.35)

Kindred Biosciences (NASDAQ KIN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018($0.36)N/AView Earnings Details
3/1/2018Q4 2017($0.33)($0.35)ViewListenView Earnings Details
11/7/2017Q3 2017($0.33)($0.29)ViewN/AView Earnings Details
8/7/2017Q2 2017($0.33)($0.29)ViewListenView Earnings Details
5/4/2017Q1 2017($0.34)($0.30)ViewListenView Earnings Details
3/1/2017Q416($0.36)($0.29)ViewListenView Earnings Details
11/7/2016Q316($0.36)($0.29)ViewListenView Earnings Details
8/8/2016Q216($0.32)($0.25)ViewN/AView Earnings Details
5/5/2016Q1 2016($0.28)($0.31)ViewN/AView Earnings Details
3/2/2016Q415($0.44)($0.32)ViewN/AView Earnings Details
11/9/2015Q3 2015($0.44)($0.36)ViewN/AView Earnings Details
8/10/2015Q2($0.42)($0.35)ViewN/AView Earnings Details
5/8/2015Q115($0.40)($0.34)ViewN/AView Earnings Details
3/12/2015Q414($0.40)($0.34)ViewN/AView Earnings Details
11/13/2014Q3 2014($0.43)($0.31)ViewN/AView Earnings Details
8/13/2014Q2 2014($0.35)($0.42)ViewN/AView Earnings Details
5/12/2014Q1 14($0.18)($0.38)ViewN/AView Earnings Details
3/6/2014($0.21)($0.40)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Kindred Biosciences (NASDAQ:KIN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Kindred Biosciences (NASDAQ KIN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 19.10%
Institutional Ownership Percentage: 64.36%
Insider Trading History for Kindred Biosciences (NASDAQ:KIN)
Institutional Ownership by Quarter for Kindred Biosciences (NASDAQ:KIN)

Kindred Biosciences (NASDAQ KIN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/2/2018Richard ChinInsiderSell20,000$8.39$167,800.002,266,071View SEC Filing  
3/16/2018Raymond TownsendDirectorSell2,670$9.45$25,231.5025,057View SEC Filing  
3/12/2018Raymond TownsendDirectorSell91$9.45$859.9523,233View SEC Filing  
1/2/2018Raymond TownsendDirectorSell6,419$9.45$60,659.5518,419View SEC Filing  
7/12/2017Park West Asset Management LlcMajor ShareholderBuy600,000$7.50$4,500,000.00View SEC Filing  
7/3/2017Richard ChinInsiderSell13,000$8.26$107,380.002,297,546View SEC Filing  
6/22/2017Richard ChinInsiderSell13,000$7.75$100,750.002,310,546View SEC Filing  
6/8/2017Park West Asset Management LlcMajor ShareholderBuy15,311$6.65$101,818.15View SEC Filing  
5/11/2017Park West Asset Management LlcMajor ShareholderBuy155,076$6.83$1,059,169.08View SEC Filing  
3/15/2017Park West Asset Management LlcMajor ShareholderBuy400,000$6.60$2,640,000.00View SEC Filing  
3/13/2017Park West Asset Management LlcMajor ShareholderBuy4,200$6.20$26,040.00View SEC Filing  
3/9/2017Park West Asset Management LlcMajor ShareholderBuy18,066$6.08$109,841.28View SEC Filing  
1/13/2017Park West Asset Management LlcMajor ShareholderBuy1,690,000$6.20$10,478,000.00View SEC Filing  
1/9/2017Park West Asset Management LlcMajor ShareholderBuy131,500$5.30$696,950.00View SEC Filing  
1/6/2017Park West Asset Management LlcMajor ShareholderBuy110,617$5.10$564,146.70View SEC Filing  
12/16/2016Park West Asset Management LlcInsiderSell18,000$4.78$86,040.00View SEC Filing  
12/14/2016Park West Asset Management LlcMajor ShareholderBuy8,334$4.75$39,586.50View SEC Filing  
12/13/2016Park West Asset Management LlcMajor ShareholderBuy1,148$4.75$5,453.00View SEC Filing  
12/12/2016Park West Asset Management LlcMajor ShareholderBuy3,112$4.74$14,750.88View SEC Filing  
3/15/2016Ernest MarioDirectorBuy30,000$3.55$106,500.0099,583View SEC Filing  
11/23/2015Raymond TownsendDirectorBuy2,000$4.00$8,000.0012,000View SEC Filing  
11/18/2015Raymond TownsendDirectorBuy2,323$4.78$11,103.9410,000View SEC Filing  
8/31/2015Raymond TownsendDirectorBuy1,677$5.85$9,810.457,677View SEC Filing  
8/14/2015Raymond TownsendDirectorBuy3,000$6.04$18,120.00View SEC Filing  
9/29/2014Oleg NodelmanDirectorBuy100,000$9.56$956,000.00View SEC Filing  
9/3/2014Ernest MarioDirectorBuy10,000$10.55$105,500.00View SEC Filing  
8/28/2014Oleg NodelmanDirectorBuy47,000$10.85$509,950.00View SEC Filing  
8/26/2014Oleg NodelmanDirectorBuy85,244$10.50$895,062.00View SEC Filing  
12/12/2013Kevin SchultzInsiderBuy4,000$7.00$28,000.00View SEC Filing  
12/12/2013Oleg NodelmanDirectorBuy400,000$7.00$2,800,000.00View SEC Filing  
12/12/2013Stephen SundlofSVPBuy1,000$7.00$7,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Kindred Biosciences (NASDAQ KIN) News Headlines

Source:
DateHeadline
Kindred Biosciences (KIN) Provides Updates on Pending Drug ApprovalsKindred Biosciences (KIN) Provides Updates on Pending Drug Approvals
www.streetinsider.com - April 25 at 4:28 PM
Kindred Biosciences Announces the Appointment of Dr. Ernest Mario and Dr. Joseph McCracken to its Board of DirectorsKindred Biosciences Announces the Appointment of Dr. Ernest Mario and Dr. Joseph McCracken to its Board of Directors
finance.yahoo.com - April 25 at 4:28 PM
Kindred Biosciences Provides Updates on Pending Drug ApprovalsKindred Biosciences Provides Updates on Pending Drug Approvals
finance.yahoo.com - April 24 at 4:30 PM
Kindred Biosciences to Announce First Quarter 2018 Financial ResultsKindred Biosciences to Announce First Quarter 2018 Financial Results
finance.yahoo.com - April 18 at 4:32 PM
Kindred Biosciences (KIN) Upgraded to "Buy" at ValuEngineKindred Biosciences (KIN) Upgraded to "Buy" at ValuEngine
www.americanbankingnews.com - April 17 at 10:29 AM
Kindred Biosciences (KIN) Given Average Rating of "Hold" by AnalystsKindred Biosciences (KIN) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - April 15 at 7:31 PM
Kindred Biosciences (KIN) Rating Increased to Buy at BidaskClubKindred Biosciences (KIN) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - April 14 at 10:43 AM
Kindred Biosciences (KIN) Upgraded to Buy at Zacks Investment ResearchKindred Biosciences (KIN) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - April 13 at 1:35 PM
-$0.38 EPS Expected for Kindred Biosciences Inc (KIN) This Quarter-$0.38 EPS Expected for Kindred Biosciences Inc (KIN) This Quarter
www.americanbankingnews.com - April 9 at 1:21 PM
Kindred Biosciences (KIN) Upgraded to Buy by Zacks Investment ResearchKindred Biosciences (KIN) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - April 9 at 12:10 PM
Kindred Biosciences (KIN) Downgraded by Zacks Investment Research to "Hold"Kindred Biosciences (KIN) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - April 9 at 8:37 AM
Kindred Biosciences (KIN) Downgraded to "Hold" at Zacks Investment ResearchKindred Biosciences (KIN) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 7 at 2:14 PM
Richard Chin Sells 20,000 Shares of Kindred Biosciences Inc (KIN) StockRichard Chin Sells 20,000 Shares of Kindred Biosciences Inc (KIN) Stock
www.americanbankingnews.com - April 4 at 11:16 PM
Kindred Biosciences (KIN) Downgraded by ValuEngineKindred Biosciences (KIN) Downgraded by ValuEngine
www.americanbankingnews.com - March 31 at 12:42 PM
Kindred Biosciences (KIN) Downgraded by Zacks Investment Research to "Sell"Kindred Biosciences (KIN) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - March 30 at 11:10 PM
Kindred Biosciences (KIN) Rating Lowered to Sell at Zacks Investment ResearchKindred Biosciences (KIN) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - March 24 at 10:54 AM
Kindred Biosciences Inc (KIN) Given Consensus Recommendation of "Hold" by AnalystsKindred Biosciences Inc (KIN) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - March 21 at 7:36 PM
Kindred Biosciences Inc (KIN) Director Raymond Townsend Sells 2,670 SharesKindred Biosciences Inc (KIN) Director Raymond Townsend Sells 2,670 Shares
www.americanbankingnews.com - March 19 at 8:30 PM
Kindred Biosciences to Present at the Oppenheimer 28th Annual Healthcare ConferenceKindred Biosciences to Present at the Oppenheimer 28th Annual Healthcare Conference
finance.yahoo.com - March 8 at 5:05 PM
 Brokerages Expect Kindred Biosciences Inc (KIN) Will Announce Earnings of -$0.38 Per Share Brokerages Expect Kindred Biosciences Inc (KIN) Will Announce Earnings of -$0.38 Per Share
www.americanbankingnews.com - March 6 at 9:43 AM
General American Investors Co. Inc. Sells 37,708 Shares of Kindred Biosciences Inc (KIN)General American Investors Co. Inc. Sells 37,708 Shares of Kindred Biosciences Inc (KIN)
www.americanbankingnews.com - March 6 at 9:04 AM
Kindred Biosciences (KIN) Upgraded to Hold at BidaskClubKindred Biosciences (KIN) Upgraded to Hold at BidaskClub
www.americanbankingnews.com - March 3 at 5:52 PM
Kindred Biosciences (KIN) Given a $11.00 Price Target by HC Wainwright AnalystsKindred Biosciences (KIN) Given a $11.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - March 2 at 11:24 PM
Kindred Biosciences (KIN) Issues Quarterly  Earnings Results, Misses Estimates By $0.02 EPSKindred Biosciences (KIN) Issues Quarterly Earnings Results, Misses Estimates By $0.02 EPS
www.americanbankingnews.com - March 2 at 10:39 AM
Kindred Biosciences, Inc. to Host Earnings CallKindred Biosciences, Inc. to Host Earnings Call
finance.yahoo.com - March 1 at 4:39 PM
Kindred Biosciences Announces Fourth Quarter and Full Year 2017 Financial ResultsKindred Biosciences Announces Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 1 at 4:39 PM
Kindred Biosciences Inc (KIN) Forecasted to Post FY2017 Earnings of ($1.21) Per ShareKindred Biosciences Inc (KIN) Forecasted to Post FY2017 Earnings of ($1.21) Per Share
www.americanbankingnews.com - February 28 at 7:40 AM
Kindred Biosciences Inc (KIN) Given Average Rating of "Buy" by BrokeragesKindred Biosciences Inc (KIN) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - February 24 at 7:38 PM
Kindred Biosciences (KIN) Scheduled to Post Earnings on TuesdayKindred Biosciences (KIN) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - February 20 at 4:12 AM
 Brokerages Expect Kindred Biosciences Inc (KIN) to Post -$0.33 EPS Brokerages Expect Kindred Biosciences Inc (KIN) to Post -$0.33 EPS
www.americanbankingnews.com - February 17 at 3:18 PM
Kindred Biosciences to Announce Fourth Quarter and Year-End 2017 Financial ResultsKindred Biosciences to Announce Fourth Quarter and Year-End 2017 Financial Results
finance.yahoo.com - February 15 at 8:54 AM
Kindred Biosciences to Participate in the Bank of America Merrill Lynch Animal Health SummitKindred Biosciences to Participate in the Bank of America Merrill Lynch Animal Health Summit
finance.yahoo.com - February 13 at 9:00 AM
Reviewing Aduro BioTech (ADRO) and Kindred Biosciences (KIN)Reviewing Aduro BioTech (ADRO) and Kindred Biosciences (KIN)
www.americanbankingnews.com - February 5 at 11:16 AM
Kindred Biosciences (KIN) Upgraded to "Hold" at ValuEngineKindred Biosciences (KIN) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - February 5 at 12:58 AM
Reviewing G1 Therapeutics (GTHX) and Kindred Biosciences (KIN)Reviewing G1 Therapeutics (GTHX) and Kindred Biosciences (KIN)
www.americanbankingnews.com - January 31 at 11:12 PM
-$0.33 EPS Expected for Kindred Biosciences Inc (KIN) This Quarter-$0.33 EPS Expected for Kindred Biosciences Inc (KIN) This Quarter
www.americanbankingnews.com - January 31 at 5:12 PM
Kindred Biosciences Inc (KIN) Receives Average Rating of "Hold" from AnalystsKindred Biosciences Inc (KIN) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - January 30 at 7:30 PM
Kindred Biosciences (KIN) Upgraded by Zacks Investment Research to "Hold"Kindred Biosciences (KIN) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - January 13 at 6:28 PM
Kindred Biosciences Inc (KIN) Receives Consensus Rating of "Hold" from BrokeragesKindred Biosciences Inc (KIN) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - January 5 at 7:26 PM
Raymond Townsend Sells 6,419 Shares of Kindred Biosciences Inc (KIN) StockRaymond Townsend Sells 6,419 Shares of Kindred Biosciences Inc (KIN) Stock
www.americanbankingnews.com - January 4 at 9:50 PM
Kindred Biosciences (KIN) Research Coverage Started at CL KingKindred Biosciences (KIN) Research Coverage Started at CL King
www.americanbankingnews.com - December 27 at 8:09 AM
Kindred Biosciences (KIN) Given "Hold" Rating at BMO Capital MarketsKindred Biosciences (KIN) Given "Hold" Rating at BMO Capital Markets
www.americanbankingnews.com - December 25 at 1:32 PM
BRIEF-KindredBio Announces Submission Of European Medicines Agency Filing For MiratazBRIEF-KindredBio Announces Submission Of European Medicines Agency Filing For Mirataz
www.reuters.com - December 21 at 11:30 AM
Kindred Biosciences (KIN) Reports Submission of European Medicines Agency Filing for MiratazKindred Biosciences (KIN) Reports Submission of European Medicines Agency Filing for Mirataz
www.streetinsider.com - December 21 at 11:30 AM
Kindred Biosciences (KIN) Rating Reiterated by AegisKindred Biosciences (KIN) Rating Reiterated by Aegis
www.americanbankingnews.com - December 19 at 8:18 AM
Kindred Biosciences Inc (KIN) Given Consensus Rating of "Buy" by AnalystsKindred Biosciences Inc (KIN) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - December 11 at 9:52 PM
Zacks: Analysts Expect Kindred Biosciences Inc (KIN) to Post -$0.33 EPSZacks: Analysts Expect Kindred Biosciences Inc (KIN) to Post -$0.33 EPS
www.americanbankingnews.com - December 11 at 5:26 PM
Kindred Biosciences (KIN) Given a $11.00 Price Target at B. RileyKindred Biosciences (KIN) Given a $11.00 Price Target at B. Riley
www.americanbankingnews.com - December 5 at 11:22 AM
Kindred Biosciences (KIN) Given a $10.00 Price Target by HC Wainwright AnalystsKindred Biosciences (KIN) Given a $10.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - December 5 at 10:34 AM
BRIEF-KindredBio Announces Positive Results From Pivotal Study Of Zimeta OralBRIEF-KindredBio Announces Positive Results From Pivotal Study Of Zimeta Oral
www.reuters.com - December 4 at 11:57 AM

SEC Filings

Kindred Biosciences (NASDAQ:KIN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Kindred Biosciences (NASDAQ:KIN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Kindred Biosciences (NASDAQ KIN) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.